Bilateral Inflammatory Breast Cancer That Developed Two Years after Treatment for Triple-negative Breast Cancer

被引:0
|
作者
Kawaguchi, Yuta [1 ,2 ]
Kuba, Sayaka [2 ]
Morita, Michi [2 ]
Meng, Xiangyue [2 ]
Hayashi, Hiroko [3 ]
Kobayashi, Kazuma [2 ]
Adachi, Tomohiko [2 ]
Hidaka, Masaaki [2 ]
Itoh, Shinichiro [2 ]
Kanetaka, Kengo [2 ]
Eguchi, Susumu [2 ]
机构
[1] Yamaguchi Prefectural Grand Med Ctr, Dept Surg, Hofu, Japan
[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg, Nagasaki, Japan
[3] Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol, Nagasaki, Japan
关键词
  bilateral inflammatory breast cancer; dose -dense chemotherapy; triple -negative breast cancer; SURVIVAL; DOXORUBICIN; CONSENSUS; PROGRAM; CELLS;
D O I
10.2169/internalmedicine.7786-21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 66-year-old woman underwent partial mastectomy and a sentinel lymph node biopsy for left breast can-cer; the pathological diagnosis was invasive ductal carcinoma (pT1aN0, pStage I, triple-negative subtype). Postoperative radiotherapy was performed. Two years later, she developed redness and induration at both breasts. The diagnosis was bilateral inflammatory breast cancer. After four cycles of dose-dense epirubicin and cyclophosphamide followed by 12 weekly paclitaxel cycles, bilateral total mastectomy and axillary lymph node dissection were performed. At the one-year follow-up after undergoing operation and radiother-apy, she remained alive without recurrence. Dose-dense treatment regimens may help patients achieve com-plete resection without short-term recurrence.
引用
收藏
页码:2387 / 2391
页数:5
相关论文
共 50 条
  • [21] Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
    Takai, Ken
    Le, Annie
    Weaver, Valerie M.
    Werb, Zena
    ONCOTARGET, 2016, 7 (50) : 82889 - 82901
  • [22] The advance of adjuvant treatment for triple-negative breast cancer
    Ge, Jingyu
    Zuo, Wenjia
    Chen, Yiyu
    Shao, Zhiming
    Yu, Keda
    CANCER BIOLOGY & MEDICINE, 2022, 19 (02) : 187 - 201
  • [23] Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
    Wesolowski, Jakub
    Tankiewicz-Kwedlo, Anna
    Pawlak, Dariusz
    CANCERS, 2022, 14 (16)
  • [24] Understanding the biology of triple-negative breast cancer
    Criscitiello, C.
    Azim, H. A., Jr.
    Schouten, P. C.
    Linn, S. C.
    Sotiriou, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 13 - 18
  • [25] Distant metastasis in triple-negative breast cancer
    Tseng, L. M.
    Hsu, N. C.
    Chen, S. C.
    Lu, Y. S.
    Lin, C. H.
    Chang, D. Y.
    Li, H.
    Lin, Y. C.
    Chang, H. K.
    Chao, T. C.
    Ouyang, F.
    Hou, M. F.
    NEOPLASMA, 2013, 60 (03) : 290 - 294
  • [26] Evaluation of treatment outcomes of triple-negative breast cancer
    Cinkaya, Ahmet
    Akin, Mustafa
    Sengul, Adem
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 150 - 154
  • [27] The application of exosomes in the treatment of triple-negative breast cancer
    Weaver, John W. W.
    Zhang, Jinyu
    Rojas, Juan
    Musich, Phillip R. R.
    Yao, Zhiqiang
    Jiang, Yong
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [28] Updates in the treatment of basal/triple-negative breast cancer
    Shastry, Mythili
    Yardley, Denise A.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2013, 25 (01) : 40 - 48
  • [29] Germline Mutations in Triple-Negative Breast Cancer
    Hahnen, Eric
    Hauke, Jan
    Engel, Christoph
    Neidhardt, Guido
    Rhiem, Kerstin
    Schmutzler, Rita K.
    BREAST CARE, 2017, 12 (01) : 15 - 19
  • [30] Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
    Qi, Yanfeng
    Fu, Xueqi
    Xiong, Zhenggang
    Zhang, Haitao
    Hill, Steven M.
    Rowan, Brian G.
    Dong, Yan
    PLOS ONE, 2012, 7 (02):